Open for bids Tender Germany ICB TOT Ref. 152322903

Conclusion not Excluding Drug Discount Agreement. Tender - 152322903

Tender notice from Germany, published on 11 Nov 2026.

Executive Summary

Title/Summary: Tender for non-exclusive rebate agreements for the active ingredient Ranibizumab in Erfurt, Germany, issued by AOK PLUS - Health Insurance for Saxony and Thuringia. The contract will be established through an Open-House model. Submission deadline: December 31, 2027.

Scope Of Work: The tender involves establishing non-exclusive rebate agreements for the drug Ranibizumab (10 mg/ml injection solution) under § 130a Abs. 8 SGB V. The contract operates under an Open-House model, allowing all interested pharmaceutical companies to participate during the specified period, provided they meet eligibility requirements. The quantities purchased will depend on demand, physician prescribing behavior, and pharmacy stock management, with no minimum purchase guarantees. Interested companies must apply for access to the participation documents via the German Procurement Portal (DTVP) and maintain confidentiality regarding the content of the agreements. The rebate agreements will terminate by December 31, 2027, unless ended earlier by the issuer.

Qualification Criterion: Bidders must be pharmaceutical companies that meet the participation requirements outlined in the documents available on the DTVP. They must submit applications electronically through the procurement portal. Confidentiality regarding the rebate agreement details is mandatory, and any unauthorized disclosure requires prior written consent from the issuer. All submitted documents must be securely destroyed if the company decides not to participate. The deadline for initial applications is December 2, 2026, with subsequent deadlines available in the project room.

Key facts

Summary
Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Ranibizumab Dfl (Atc Code According to Who: S01la04)
TOT Ref. No.
152322903
Document Ref. No.
Login to see
Country
Germany
Notice type
Tender
Competition
ICB
Publication date
11 Nov 2026
Bid deadline
31 Dec 2027
EMD
Refer Document
Tender value
Refer Document
Purchaser ownership
Public
Financier
Self Financed

CPV classification

Purchaser details

Purchaser contact is for registered users

Login to see details

Tender details

Tender details are for registered users

Login to see details

Documents

Tender Notice
Login to view

Similar tenders

Germany Public Procurement Intelligence

Frequently asked questions

The last date to submit a bid for Conclusion not Excluding Drug Discount Agreement. According to Section 130A Paragraph 8 Sgb V through an Open House Model for the Active Ingredient Ranibizumab Dfl (Atc Code According to Who: S01la04) is 31 Dec 2027. Submit before this date to be considered.

This tender has been issued by AOK PLUS - THE HEALTH INSURANCE FUND FOR SAXONY AND THURINGIA in Germany.

The tender value is not disclosed; please refer to the tender document. EMD / bid security details are provided in the tender document.

This tender is Self Financed

The tender is classified under the following CPV code(s): 33600000 - Pharmaceutical products.

The tender notice and related documents are listed in the Documents section above. Select a document to view or download it. Please log in or register to access the documents. If you cannot find additional documents in the Documents section, please log in to your account and Send Document Request from your account section.

The TendersOnTime reference is 152322903. The purchaser document reference is available after login.

See the Similar Tenders section on this page or browse other tenders from Germany.

This tender falls under Materials and Products, Technology and Equipment in Germany. Suppliers in these sectors can track similar Germany tenders using CPV-based alerts.